Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma

Area of Science:

• Immunology
• Veterinary Oncology
• Cell Therapy

Background:

• Osteosarcoma is a prevalent and highly metastatic bone cancer in dogs with limited therapeutic advancements.
• Current treatments, including chemotherapy, have not significantly improved outcomes for osteosarcoma.
• Osteosarcoma is immunogenic, suggesting potential for immunotherapy, particularly for microscopic metastases.

Purpose of the Study:

• To review the rationale for adoptive natural killer (NK) cell immunotherapy in canine osteosarcoma.
• To discuss NK cell biology, the immunosuppressive tumor microenvironment, and its relevance to osteosarcoma.
• To explore the manufacturing of ex vivo expanded NK cells for dogs and their clinical applications.

Main Methods:

• Review of existing literature on NK cell biology and adoptive cell therapy.
• Analysis of the immunosuppressive mechanisms in the osteosarcoma microenvironment, including TGFβ.
• Examination of methods for ex vivo expansion of NK cells for canine immunotherapy.

Main Results:

• NK cells are crucial for innate immunity and can target stressed/cancer cells independently of MHC.
• Adoptive NK cell therapy hypothesizes restoring innate immunity defects caused by cancer.
• The immunosuppressive tumor microenvironment in osteosarcoma poses challenges for effective NK cell function.

Conclusions:

• Adoptive NK cell immunotherapy presents a promising therapeutic avenue for canine osteosarcoma.
• Restoring NK cell function through adoptive transfer could overcome cancer-induced immune suppression.
• Further research into manufacturing and clinical application of canine NK cells is warranted for osteosarcoma and other cancers.